Fermentalg SA

Fermentalg operates with a current liquidity position of EUR 6.62 million in cash and equivalents, while its total liabilities amount to EUR 11.26 million. The company's debt-to-equity ratio is 0.2, indicating a relatively low leverage position. However, the company reported a negative operating cash flow of EUR -6.59 million and a free cash flow of EUR -7.91 million, suggesting ongoing cash burn. The current ratio of 1.96 implies the company has sufficient current assets to cover its current liabilities. In terms of profitability, Fermentalg reported a net loss of EUR -9.44 million and an operating loss of EUR -9.38 million. The return on equity (ROE) is -37.48%, and the return on assets (ROA) is -25.9%, both significantly below the industry median for biotechnology firms. The gross profit margin is 17.13%, which is also below the industry average, indicating inefficiencies in cost management or pricing power. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks, particularly in the biotechnology and healthcare sectors. The company's operations are primarily based in France, and it does not report revenue by geographic region, which limits visibility into regional performance and risk exposure. Fermentalg's growth trajectory is currently negative, with a net loss and declining cash reserves. The company has not provided specific guidance for the next fiscal year, but the continued negative operating cash flow suggests that growth is not being funded by internal cash generation. The company's capital expenditures of EUR -1.54 million indicate ongoing investment in infrastructure, but the negative free cash flow suggests that these investments are not yet generating returns. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative cash flows and operating losses suggest potential liquidity constraints in the medium term. The dilution potential is currently low, as the number of shares outstanding has not changed between basic and diluted shares. Recent events include analyst estimates that suggest a mean price target of EUR 0.72, with a median of EUR 0.72 and a high of EUR 0.80. The mean recommendation is 1.50, indicating a slight positive bias from analysts, with one strong buy and one buy recommendation.